22nd Century Group, Inc (NASDAQ:XXII) Short Interest Update

22nd Century Group, Inc (NASDAQ:XXII) was the target of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totaling 168,162 shares, a decrease of 34.0% from the November 30th total of 254,700 shares. Based on an average daily trading volume, of 187,666 shares, the short-interest ratio is presently 0.9 days. Currently, 2.4% of the shares of the company are sold short. Currently, 2.4% of the shares of the company are sold short. Based on an average daily trading volume, of 187,666 shares, the short-interest ratio is presently 0.9 days.

22nd Century Group Trading Down 8.2%

Shares of XXII opened at $0.76 on Wednesday. The stock’s 50 day moving average is $1.10 and its two-hundred day moving average is $2.63. 22nd Century Group has a twelve month low of $0.75 and a twelve month high of $287.27. The firm has a market capitalization of $5.32 million, a PE ratio of -0.01 and a beta of 1.11.

22nd Century Group (NASDAQ:XXII) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($16.79) by $15.73. 22nd Century Group had a negative return on equity of 184.33% and a negative net margin of 37.64%.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 22nd Century Group in a research note on Monday. Wall Street Zen upgraded 22nd Century Group from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On 22nd Century Group

A hedge fund recently raised its stake in 22nd Century Group stock. Anson Funds Management LP increased its stake in 22nd Century Group, Inc (NASDAQ:XXII) by 197.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 98,212 shares of the biotechnology company’s stock after purchasing an additional 65,174 shares during the quarter. Anson Funds Management LP owned 1.41% of 22nd Century Group worth $166,000 at the end of the most recent quarter. 18.06% of the stock is currently owned by institutional investors.

About 22nd Century Group

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.